Clinical Trial

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-08-20; most recent amendment 2026-01-08.
Trial Details
NCT Number NCT03258320
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Fudan University, Qilu Hospital of Shandong University
Conditions Prostate Cancer Patients
Enrollment 300 participants
Start Date 2015-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-12